Gastritis is an inflammatory condition of the gastric mucosa induced by Helicobacter pylori infection, autoimmunity and chemical agents. Although Sydney system was devised for semiquantitative methods of gastritis, most physicians and pathologists consider it to be too complex and bothersome to use for routine diagnosis. Moreover, Sydney system does not reflect the overall gastritis condition and it cannot directly predict increased gastric cancer risk. To overcome these limitations, a new gastritis staging method, called Operative Link for Gastritis Assessment (OLGA) system was designed by the international group of gastroenterologists and pathologists. This system may achieve simplification of reports for the gastritis condition and it can aid in predicting gastric cancer risk and planning patient surveillance. Herein, we reviewed the routine evaluation methods, clinical implication and advantage/limitations of the OLGA system. (Korean J Helicobacter Up Gastrointest Res 2013;13:20-24)
INTRODUCTION
Gastritis is defined as an inflammatory condition occurred in gastric mucosa and it displays characteristic extent and distribution according to causal factors, severity or duration. 1 Helicobacter pylori affected in about half of populations in the world, is the major cause of gastritis. Other sources include chemical agents and autoimmunity. [1] [2] [3] Comprehensive assessment of clinical examination, serologic test (e.g., antibodies for infection or autoimmunity), endoscopy and histologic examination could be diagnostic tools for patients with gastritis. [4] [5] [6] [7] [8] Typical histologic findings of gastritis are summarized as below: (1) chronic inflammaroty infiltrates in lamina propria (lymphocytes, plasma cells and histiocytes), (2) active inflammatory infiltrates in lamina propria and gastric glands (neutrophils and eosinophils) and (3) loss of glandular units with replacement into fibrosis and smooth muscle proliferation, called as atrophy. 2 Gastritis is linked with development of gastric cancer. 9 Previous epidemiologic and biologic studies investigated that intensity and distribution pattern of mucosal inflammation and atrophy are associated with carcinogenesis of gastric cancer and H. pylori are considered as a grade 1 carcinogen of gastric cancer. [10] [11] [12] Extent of inflammation and atrophy has also relevance to gastric cancer occurrence. 13 In despite of these results for the correlation of gastritis and gastric cancer, it is difficult to assess individual risk of gastric cancer development because accurate significance or relationship of environmental, biological and immunological factors has not yet been determined. 1 Sydney system is one of the most representative histologic methods for gastritis assessment adjusting semi-quantitative 4-tier scale. Sydney system was first established in 1990. Four years later, it was modified and updated into Houston-updated Sydney System. Sydney system recommends an itemized description of various microscopic findings including lymphoplasma cell infiltrates, neutrophilic infiltrates, intestinal metaplasia, mucosal atrophy and H. pylori. Severity/intensity of each factors is quantitatively expressed using 4 grading system, ranging from 0 (absence) to 3 (marked).
14 After then, in April 2005, international group of gastroenterologists and pathologists (Operative Link for Gastritis Assessment, OLGA) held a meeting for reassessment of Sydney system and designa- ted gastritis staging system such as hepatitis. OLGA system for gastritis was generated in this meeting. 13 OLGA system is based on the knowledge that atrophic change (severity and extent) is one of the most reliable factor of gastritis progression and prediction of gastric cancer development. 1, 3 Routine biopsy sampling can make a consistent and objective evaluation of mucosal atrophy and accurate mapping leading to staging of gastritis. 13 OLGA system can be helpful to predict the risk of gastric cancer development and assume the causal factor in gastritis. Herein we described methods of OLGA staging system and their clinical significance depending on each stage.
GASTRITIS STAGING:
THE OLGA SYSTEM
Biopsy sampling and processing
As mentioned above, it is important to define and clarify the extent and distribution of inflammatory and atrophic lesions for evaluation of cancer risk and causal factor of gastritis. [10] [11] [12] Multi-regional, deep biopsy is necessary for mapping of gastric atrophy/inflammation and efficient evaluation for H. pylori. Routine biopsy sampling has to be performed in oxyntic, antral and incisura angularis mucosa. Anterior and posterior walls of oxyntic and antral mucosa should be sampled. And then other additional focal lesions can be obtained. 2, 14, 15 Specimen from antrum put into a bottle and specimens from oxyntic and incisura angularis mucosa put into another bottle, together. For more extensive examination of oxyntic mucosa, separate two regions of lesser and greater curvature may be biopsied and put into third sample bottle. 2 Without tissue injury, materials should be fixed into formaldehyde as soon as possible.
Evaluation of gastric atrophy and gastritis staging
Ideally gastric atrophy should be evaluated in perpendicularly sectioned tissue exhibiting whole layers of gastric mucosa from foveolar epithelium to muscularis mucosa. International Group of Gastrointestinal Pathologists (Atrophy Club) made an algorithm for assessment of atrophic change: Absent; indefinite category causing to failure of valid assessment by severe inflammatory condition and shallow biopsy; Present (Fig. 1) . 1 Gastric atrophy is a loss of appropriate normal glandular unit and it is subdivided into two different phenotypes by metaplastic change. One type displays shrinkage and vanishing of glandular unit with proliferative fibrotic extension of lamina propria. Total area of glandular unit is lower, but remnant glandular units are normal in appearance.
Another type of atrophy is accompanied with metaplastic change, such as intestinal or pseudopyloric metaplasia. Although total number of glands are not reduced, metaplastic change leads to loss of appropriate glands. 16 Grading of atrophy in each biopsied specimen follows 4-tiered scale from 0 to 3 depending on percentage of atrophic glands (no atrophy, 0%, score=0; mild atrophy, 1∼ 30%, score=1; moderate atrophy, 31∼60%, score=2; severe atrophy, ＞60%, score=3). After then, the OLGA stage is set by combination of overall score of oxyntic and antral mucosa (Fig. 2) .
3. Clinical implication of the OLGA system 1) Stage 0 gastritis As Fig. 2 , stage 0 represents the state of no atrophic change in five standardly biopsied (oxyntic, incisura angularis and antral) gastric mucosa. However, "indefinite for atrophy" should not be considered as stage 0 because the indefinite status means that it is impossible to make a definite diagnosis with given specimen and it is necessary for inflammation treatment and deep biopsy to appro- 
4) Stage 3 gastritis
Stage 3 gastritis is a moderate to severe atrophic condition concurrently involved in both oxyntic and antral mucosa. Multifocal atrophic gastritis or corpusrestricted atrophic gastritis induced by autoimmunity should be considered in this condition. Stage 3 gastritis is classified as an increased gastric cancer risk groups and rarely intraepithelial neoplasm or invasive cancer may be coexist with this lesion. 18 
5) Stage 4 gastritis
Severe atrophic change in whole gastric walls is noted in stage 4 gastritis, which is epidemiologically correlated with progressive phases of multiple atrophic gastritis. Gastric carcinogenesis (both invasive and non-invasive lesions) could be likely to be occurred in diffusely atrophic area. The extent of atrophic area has a positive correlation with gastric cancer risk and atrophic area with metaplastic change also displays genetic and morphologic alterations resulting in cancer development. 19 Therefore patients with OLGA stage 3 and 4 gastritis are increased risk group of gastric cancer and should be fulfilled with careful follow up study.
Application of OLGA system
Atrophic status of gastric mucosa (extent and severity) and H. pylori infection are most reliable factors for gastric cancer prediction. Using routine biopsy protocol and histologic evaluation by OLGA system allow reasonable and beneficent managements for gastritis patients. Graham and Asaka 3 classified patients as four gastric cancer risk groups using OLGA system and they also provided a new strategy for assessment of gastritis patients reflecting the individual possibility of cancer development risk (Table 1 and Fig. 3 ). According to their proposal, H. pylori infection is first evaluated. If H. pylori are infected, eradication of this organism is followed. And then surveillance plan of patients can be established by atrophic status (OLGA stage). 3 
Advantage and limitation of OLGA system
The Houston-updated Sydney System's guideline has been commonly used for gastritis grading. 14 The new OLGA system could be an effective and facile method for understanding the cause of gastritis and prediction of gastric cancer. Even though its limitations and unfamiliarity, further practical application and investigation are needed for improving the methods of gastritis evaluation and gastric cancer prediction.
